Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) + Comparator: Comparator: Placebo (unspecified)

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rotavirus

Conditions

Rotavirus, Gastroenteritis

Trial Timeline

Aug 1, 2008 → Aug 1, 2009

About Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) + Comparator: Comparator: Placebo (unspecified)

Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) + Comparator: Comparator: Placebo (unspecified) is a phase 3 stage product being developed by Merck for Rotavirus. The current trial status is completed. This product is registered under clinical trial identifier NCT00718237. Target conditions include Rotavirus, Gastroenteritis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00718237Phase 3Completed